A double-blind placebo-controlled trial of topiramate treatment for essential tremor
- 9 July 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 59 (1) , 132-134
- https://doi.org/10.1212/wnl.59.1.132
Abstract
The safety and efficacy of topiramate (400 mg/d or maximum tolerated dose) as monotherapy or adjunctive treatment of essential tremor were investigated in a placebo-controlled, crossover study (n = 24). Topiramate resulted in significantly greater reductions from baseline based on normalized scores for a clinical rating of tremor location/severity, specific motor tasks/functional disabilities, and tremor-resultant functional disabilities. Most common adverse events were appetite suppression/weight loss and paresthesias.Keywords
This publication has 7 references indexed in Scilit:
- Essential TremorNew England Journal of Medicine, 2001
- Topiramate and essential tremorAnnals of Neurology, 2000
- Topiramate as Add‐On Therapy: Pooled Analysis of Randomized Controlled Trials in AdultsEpilepsia, 2000
- An Overview of the Preclinical Aspects of Topiramate: Pharmacology, Pharmacokinetics, and Mechanism of ActionEpilepsia, 2000
- The effect of acetazolamide on essential tremorNeurology, 1992
- Treatment of Essential Tremor With MethazolamideMayo Clinic Proceedings, 1991
- Essential TremorClinical Neuropharmacology, 1989